Min Yang

Dr. Min Yang

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 June 2023 in International Urology and Nephrology
Verified
Journal Article
Open access
PDF file
WWWenhui Wu
Wenhui Wu
XLXiurong Li
Xiurong Li
JDJia Di
Jia Di
HZHua Zhou
Hua Zhou
HNHongyan Niu
Hongyan Niu
MYMin Yang
Min Yang
Objectives: Multiple observational studies have shown that low serum level of 25-hydroxyvitamin D (25(OH)D) in patients with chronic kidney disease (CKD) have been associated with a faster progression of kidney disease and a higher risk of all-cause mortality. We aim to assess the association between dietary inflammatory index (DII) with Vitamin D in adults with CKD. Method: The National Health and Nutrition Examination Survey appropriated participants from 2009 to 2018 were enrolled. The patients who were under the age of 18, pregnant, and having incomplete data were excluded. DII score were calculated based on a single 24-h dietary recall interview for each participant. Mutivariable regression analysis and subgroup analysis were utilized to determine the independent associations between vitamin D with DII in CKD patients. Results: In total, 4283 individuals were finally included. The results showed a negative association between DII scores and 25(OH)D with statistical significance (β = – 1.83, 95% CI – 2.31, – 1.34, P < 0.001). In subgroup analysis stratified by gender, low eGFR, age and diabetes, the negative association between DII scores and 25(OH)D was still significant (all P for trend < 0.05). The results from interacion test indicated that the magnitude of the association was the same for the population with and without low eGFR (P for interacion = 0.464). Conclusion: Higher consumption of pro-inflammatory diet correlates negatively with the 25(OH)D level in CKD patients with and without low eGFR. Anti-inflammatory diet management may reduce the reduction of vitamin D in CKD patients.

19 September 2024 in BMC Nephrology
Verified
Journal Article
Open access
PDF file
YNYanhong Ni
Yanhong Ni
WWWenhui Wu
Wenhui Wu
HZHua Zhou
Hua Zhou
MLMin Li
Min Li
XZXiying Zhu
Xiying Zhu
MYMin Yang
Min Yang
The utilization of ultrapure dialysate has been shown to decrease dialysate contamination and mitigate inflammatory responses. The central dialysate delivery system (CDDS) has the potential to attain a level of purity similar to ultrapure dialysate. Nevertheless, there is limited research examining the impact of CDDS on inflammation in comparison to single-patient dialysis fluid delivery system(SPDDS). This study aims to investigate the effects of CDDS utilizing ultrapure dialysate on ameliorating the microinflammatory state in hemodialysis patients. A retrospective cohort clinical study enrolled a total of 125 hemodialysis patients, with 58 patients from the CDDS unit and 67 patients from the SPDDS unit. Each participant was monitored for a period of 6 months, and the repeated measurement data was analyzed using a generalized linear mixed models (GLMM). The average age of the studty cohort was 56.22 ± 12.64 years. The GLMM analysis showed a significant time*group interaction effect on hs-CRP changes over the follow-up period (β = -1.966, FTime* CDDS group = 13.389, P < 0.001). A linear mixed model analysis with random slope showed that a different slope was observed between CDDS group and SPDDS group (βCDDS =—0.793; βSPDDS = 0.791), indicating a decreased hs-CRP levels in CDDS group, while increased in the SPDDS group over the follow-up period. However, no significant time*group interaction effect were observed on albumin and β2-microglobulin levels during follow-up period(β2-microglobulin: β = -0.658, FTime* CDDS group = 1.228, P = 0.269; albumin: β = 0.012, FTime* CDDS group = 1.429, P = 0.233). Using ultrapure dialysate in the CDDS is associated with an improvement in hs-CRP levels compared to standard dialysate, which might confer long-term clinical advantages.

10 September 2023 in Therapeutic Apheresis and Dialysis
Verified
Journal Article
Closed access
WWWenhui Wu
Wenhui Wu
XLXiurong Li
Xiurong Li
JDJia Di
Jia Di
HZHua Zhou
Hua Zhou
HNHongyan Niu
Hongyan Niu
MYMin Yang
Min Yang

12 February 2024 in Renal Failure
Verified
Journal Article
Open access
WWWenhui Wu
Wenhui Wu
NHNan Hu
Nan Hu
XLXiurong Li
Xiurong Li
JDJia Di
Jia Di
HZHua Zhou
Hua Zhou
MYMin Yang
Min Yang
To explore independent influencing factors for clinical efficacy of roxadustat in hemodialysis patients. Hemodialysis patients treated with roxadustat were enrolled. The plasma trough concentrations of roxadustat were measured using liquid chromatography-tandem mass spectrometry (LC-MS/MS). A multiple logistic regression model was established to determine the factors that affect clinical efficacy of roxadustat in patients undergoing hemodialysis. A total of 67 hemodialysis patients were enrolled in the study. The results showed that age, blood trough concentration of roxadustat, and baseline hemoglobin (Hb) level were independent factors of clinical efficacy of roxadustat (OR = 1.06, p = .025 for age; OR = 1.001, p = .037 for plasma concentration; and OR = 0.941, p = .003 for baseline Hb), with an AUC score of 0.859. Age, blood trough concentration of roxadustat, and baseline Hb level were independent influencing factors of the response to roxadustat in hemodialysis patients.

22 October 2022 in Sleep and Breathing
Verified
Journal Article
Closed access
PDF file
QLQing-Yuan Liu
Qing-Yuan Liu
MYMin Yang
Min Yang
YSYu-Jing Sheng
Yu-Jing Sheng
XCXiaofang Chen
Xiaofang Chen
CWCai-Shan Wang
Cai-Shan Wang
CLChun-Feng Liu
Chun-Feng Liu